Received Jul 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | ES49H | — |
| MENB | MENINGOCOCCAL B (TRUMENBA) | PFIZER\WYETH | 2 | — | — |
received a dose of Trumemba instead of a dose of Bexsero as a second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of interchange of vaccine products in a 19-year-old female patient who received Men B NVS (Bexsero) (batch number ES49H, expiry date 31-MAY-2027) for prophylaxis. Co-suspect products included Meningococcal vaccine B rfHbpA/fHbpB (Trumenba) for prophylaxis. On 26-JUL-2024, the patient received the 1st dose of Bexsero. On an unknown date, the patient received the 2nd dose of Trumenba. On an unknown date, an unknown time after receiving Bexsero and Trumenba, the patient experienced interchange of vaccine products (Verbatim: received a dose of Trumemba instead of a dose of Bexsero as a second dose). The outcome of the interchange of vaccine products was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 27-JUN-2025 A pharmacist called asking advice regarding a 19-year-old female patient dosing schedule. Patient received Bexsero 1st dose on 26th July 2024. Then the patient received Trumenba by mistake instead of Bexsero which led to interchange of vaccine products. Reporter questioned that did the patient had to get the next dose of Bexsero.